<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04427254</url>
  </required_header>
  <id_info>
    <org_study_id>PBN_2020_16</org_study_id>
    <nct_id>NCT04427254</nct_id>
  </id_info>
  <brief_title>Study of the Sars-Cov2 Neuroinvasiveness - COVID19</brief_title>
  <acronym>CORONEVRAXE</acronym>
  <official_title>Study of the Sars-Cov2 Neuroinvasiveness - COVID19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sars-Cov2 (COVID-19) may invade the CNS inducing neurological diseases such as anosmia,
      ageusia, encephalitis, ischemic or hemorrhagic stroke. Management of severe neurological
      complications in COVID-19 patients may require ventricular cerebrospinal fluid drainage and
      cranial decompression. During surgery, cerebrospinal fluid, meninges and brain parenchyma can
      be safely removed from the patient. In this study, COVID-19 patients will be evaluated first,
      for the presence of Sars-Cov2 in the cerebrospinal fluid and/or biopsies and second, for the
      consequences of Sars-Cov2 neuroinfection in terms of inflammatory and immune responses.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with COVID-19 positive samples/biopsies</measure>
    <time_frame>At the time of the inclusion</time_frame>
    <description>COVID-19 RT-PCR test</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>Neurological biological samples</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies</intervention_name>
    <description>Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies</description>
    <arm_group_label>Neurological biological samples</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID-19 patients requiring an external ventricular drain, a decompressive craniectomy
             or an intracranial hematoma surgery

        Exclusion Criteria:

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre BOURDILLON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation A. de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Am√©lie YAVCHITZ, MD</last_name>
    <phone>(0)148036454</phone>
    <phone_ext>+33</phone_ext>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondation A de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre BOURDILLON, MD</last_name>
      <phone>(0)1 48 03 68 22</phone>
      <phone_ext>+33</phone_ext>
      <email>pbourdillon@for.paris</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sars-Cov2 neuroinvasiveness</keyword>
  <keyword>COVID-19 RT-PCR test</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

